FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1316-1317 May 5, 1994 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Nightingale, S. D. PubMed Citation

To the Editor: The results of two double-blind, randomized, placebo-controlled trials published in the Journal (Sept. 16 issue)¹ have shown that prophylactic treatment with rifabutin (300 mg per day) significantly reduces the incidence of Mycobacterium avium complex bacteremia. A Special Report in the same issue² further recommends rifabutin prophylaxis in adults and adolescents with human immunodeficiency virus infection and CD4+ counts of 100 cells or less per cubic millimeter and suggests that effective primary prophylaxis could improve the patients' quality of life and survival.

Fluconazole, a potent inhibitor of cytochrome P-450, significantly (P<0.01) increases both the maximal concentration and the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Piscitelli, S. C., Gallicano, K. D. (2001). Interactions among Drugs for HIV and Opportunistic Infections. NEJM 344: 984-996 [Full Text]  
• MALOUF, M. A., GLANVILLE, A. R. (1999). The Spectrum of Mycobacterial Infection after Lung Transplantation. Am. J. Respir. Crit. Care Med. 160: 1611-1616 [Abstract] [Full Text]  
• RIDZON, R., WHITNEY, C. G., MCKENNA, M. T., TAYLOR, J. P., ASHKAR, S. H., NITTA, A. T., HARVEY, S. M., VALWAY, S., WOODLEY, C., COOKSEY, R., ONORATO, I. M. (1998). Risk Factors for Rifampin Mono-resistant Tuberculosis. Am. J. Respir. Crit. Care Med. 157: 1881-1884 [Abstract] [Full Text]